Research, career guides, and industry analysis for practitioners entering the Ibogaine field. Written by the Texas Ibogaine Institute team.
In 2023, the Texas Legislature passed SB 2355, committing $50 million in state funding to Ibogaine clinical trials at UT Health San Antonio and other institutions. This is not a fringe experiment — it is a state-backed medical initiative that will generate demand for thousands of trained practitioners over the next decade.
Integration coaching is one of the fastest-growing roles in the psychedelic medicine space. Unlike clinical facilitators who are present during the Ibogaine session itself, integration coaches work with clients in the weeks and months after their experience — helping them process insights, build new habits, and prevent relapse.
There are currently over 80 licensed Ibogaine clinics operating in Mexico and Costa Rica, serving an estimated 10,000–15,000 patients annually from the United States alone. That number is growing rapidly. And the single biggest operational constraint these clinics face is not funding, not marketing, and not patient demand — it is finding qualified clinical facilitators.
The psychedelic medicine space is expanding rapidly, with psilocybin, MDMA, ketamine, and Ibogaine all gaining clinical traction. But practitioners who assume that training in one psychedelic translates to competency with another are making a potentially dangerous mistake — particularly when it comes to Ibogaine.
In 2023, over 4,200 Texans died from drug overdoses — the majority involving opioids. Texas has invested hundreds of millions in traditional treatment approaches, with limited success. The state's $50 million investment in Ibogaine clinical trials represents a recognition that new approaches are needed — and that Ibogaine's unique mechanism of action offers something traditional treatments cannot.
Join practitioners across Texas who are building credibility in the fastest-growing field in medicine.